Form 4 for XLO Xilio Therapeutics, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2025-12-31 · accession 0001193125-26-002518 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-01-05 | 2026-01-01 | XLO | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | M - OptEx | — | +5,000 | 8,197 | +156% | — |
| DT | 2026-01-05 | 2026-01-02 | XLO | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | S - Sale+OE | $0.64 | -1,826 | 6,371 | -22% | -$1,169 |
| DT | 2026-01-05 | 2025-12-31 | XLO | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | A - Grant | $0.00 | +95.2K | 95.2K | New | $0 |
| DT | 2026-01-05 | 2026-01-01 | XLO | Brennan Kevin M. | SVP, Fin AND ACCOUNTING | M - OptEx | $0.00 | -5,000 | 10.0K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-01 | M | A | 5,000 | — | 8,197 | D | — | — | (F1) Restricted stock units ("RSUs") convert to stock on a one-for-one basis. |
| 2 | Common | Common Stock | 2026-01-02 | S | D | 1,826 | $0.64 | 6,371 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2025-12-31 | A | A | 95,221 | $0.00 | 95,221 | D | $0.84 · — to 2035-10-07 | 95,221 Common Stock | (F3) On October 8, 2025, the Board of Directors (the "Board") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as "Tranche 3 Options" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met. (F4) The portion of Tranche 3 Options that achieved the vesting condition s equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025. (F5) This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date. |
| 4 | Derivative | Restricted Stock Units | 2026-01-01 | M | D | 5,000 | $0.00 | 10,000 | D | — · — to — | 5,000 Common Stock | (F1) Restricted stock units ("RSUs") convert to stock on a one-for-one basis. (F6) These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025. |